CoronaVac, a Covid vaccine produced by the Chinese pharmaceutical company Sinovac Biotech, has been shown to provide 83.5 percent protection against clinical Covid-19 disease and 100% protection against hospitalisation. The first results of a phase 3 study of CoronaVac show that the vaccination generates a strong antibody response.
There were no serious adverse events or fatalities recorded throughout the trials, which included over 10,000 people in Turkey. The majority of the responses were minor, such as tiredness and discomfort at the injection site, and occurred within seven days following the injection.
CoronaVac has been licenced for use in 22 countries, notably Thailand, Brazil, Uruguay, Ukraine, and Albania, and has been in phase 3 testing in Brazil, Indonesia, Chile, and Turkey since mid-2020.
Discussion about this post